Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus irinotecan in advanced second-line esophageal squamous cell carcinoma
ChiCTR2000039451Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab and irinotecan in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
camrelizumabirinotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000039451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039451.